(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -12.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Sarepta Therapeutics's revenue in 2026 is $1,974,344,000.On average, 27 Wall Street analysts forecast SRPT's revenue for 2026 to be $198,367,545,438, with the lowest SRPT revenue forecast at $185,903,556,960, and the highest SRPT revenue forecast at $212,415,939,231. On average, 26 Wall Street analysts forecast SRPT's revenue for 2027 to be $152,419,791,303, with the lowest SRPT revenue forecast at $94,147,476,358, and the highest SRPT revenue forecast at $196,783,140,123.
In 2028, SRPT is forecast to generate $147,983,456,421 in revenue, with the lowest revenue forecast at $96,671,962,160 and the highest revenue forecast at $180,094,070,805.